Search

Search Results

• CO16 | The predictive value of high-sensitivity C-reactive protein for assessing thrombosis risk in non-small cell lung cancer P. Gomez-Rosas^1,2, M. Marchetti^1,3, L. Russo¹, C.J. Tartari¹, S. Bolognini¹, C. Ticozzi¹, F. Schieppati¹, A. D’Alessio⁴, R. Labianca⁵, A. Falanga^1,3 All on behalf of the Hypercan Investigators | ¹Hospital Papa Giovanni XXIII, Bergamo, Italy; ²Cardiovascular Research Institute Maastricht, CARIM, Maastricht University, Maastricht, the Netherlands; ³School of Medicine and Surgery, University of Milan Bicocca, Italy; ⁴University Vita-Salute San Raffaele, Milan, Italy; ⁵Fondazione ARTET Onlus, Bergamo, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.220

  636

  PDF: 16

• CO14 | Inflammation and fibrinolysis biomarkers as predictors of cancer risk in healthy subjects: results from the hypercan study C. Ticozzi¹, S. Bolognini^1,2, P. Gomez-Rosas^1,3, L. Russo^1,2, Cj. Tartari^1,2, F. Schieppati^1,2, G. Sampietro⁴, L. Barcella¹, M. Marchetti^1,2, A. Falanga^1,2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ⁴Unit of Epidemiology and Statistics, ATS Bergamo, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.218

  668

  PDF: 21

• CO08 | The utility of urine qualitative assessment for direct oral anticoagulants in routine clinical practice F. Schieppati^1,2, P. Gomez-Rosas^1,3, C. Ambaglio¹, V. Brusegan¹, Oc. Cretu^1,2, E. Galimberti¹, F. Zunino¹, L. Barcella¹, J. Harenberg^4,5, A. Falanga^1,2, M. Marchetti^1,2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ⁴Ruprecht Karls University of Heidelberg, Germany; ⁵Germany DOASENSE GmbH, Heidelberg, Germany

  22-10-2025

  https://doi.org/10.4081/btvb.2025.212

  749

  PDF: 21

• CS04 | Association between elevated plasma levels of tissue plasminogen activator and occult cancer risk: a nested case-cohort analysis in 10,294 healthy subjects S. Bolognini^1,2, C. Ticozzi¹, P. Gomez-Rosas^1,3, L. Russo^1,2, Cj. Tartari^1,2, F. Schieppati^1,2, G. Sampietro⁴, L. Barcella¹, M. Marchetti^1,2, A. Falanga^1,2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, The Netherlands; ⁴Unit of Epidemiology and Statistics, ATS Bergamo, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.201

  696

  PDF: 31

• CO37 | Assessment of clotting factor activity and sterility in thawed fresh frozen plasma supplied to helicopter emergency medical services for prehospital transfusion D. Romeo¹, M. Marchetti^1,2, M. Testa¹, A. Motta¹, P. Gomez-Rosas¹, G. Ravasio¹, F. Daminelli³, L. Barcella¹, A. Falanga^1,2 | ¹Immunohematology and Transfusion Medicine Department, Hospital Papa Giovanni XXIII, Bergamo; ²School of Medicine and Surgery, University Milano Bicocca, Milan; ³Anesthesia and Resuscitation Department, Hospital Papa Giovanni XXIII, Bergamo, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.244

  685

  PDF: 18

• CO010 | MAPPING HEMOSTATIC BIOMARKER EXPRESSION ACROSS CANCER TYPES AND STAGES WITHIN THE HYPERCAN COHORT P. Gómez-Rosas^1|2, D. Romeo¹, S. Bolognini¹, C. Ticozzi¹, F. Schieppati^1|4|5, A. D’Alessio³, R. Labianca³, L. Barcella^1|4|5, A. Falanga^3|5, M. Marchetti^1|4|5 | ¹Hospital Papa Giovanni XXIII, Bergamo, Italy; ²Hospital de Oncología, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México, México; ³Fondazione ARTET Onlus, Bergamo, Italy; ⁴ERN EuroBloodNet; ⁵School of Medicine and Surgery, University of Milan Bicocca, Italy. On behalf of the HYPERCAN Investigators

  Marina Marchetti

  26-10-2026

  https://doi.org/10.4081/btvb.2026.712

  36

  PDF: 9
• 

  PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti^1|2|3, P. Gomez-Rosas^1|4|5, S. Bolognini¹, C. Ticozzi¹, D. Romeo¹, F. Schieppati^1|3, L. Barcella^1|3, F. Petrelli⁶, A. D'Alessio⁷, R. Labianca⁷, A. Falanga^1|2|3 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; ³ERN EuroBloodNet; ⁴Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; ⁵Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; ⁶Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; ⁷Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.538

  473

  PDF: 107
• 

  PO43 | ELEVATED CIRCULATING TISSUE PLASMINOGEN ACTIVATOR LEVELS PREDICT GASTROINTESTINAL AND BREAST CANCER RISK: A PROSPECTIVE NESTED CASE-COHORT STUDY S. Bolognini^1|2, C. Ticozzi¹, P. Gomez-Rosas^1|3, F. Schieppati^1|2, G. Sampietro⁴, L. Barcella¹, M. Marchetti^1|2, A. Falanga^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; ⁴Unit of Epidemiology and Statistics, ATS Bergamo, Italy

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.537

  472

  PDF: 113
• 

  PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY P. Gómez-Rosas^1|2|, D. Romeo¹, S. Bolognini¹, C. Ticozzi¹, F. Schieppati¹, A. D’Alessio⁴, R. Labianca⁴, A. Falanga^1|5|6, M. Marchetti^1|5|6 | ¹Hospital Papa Giovanni XXIII, Bergamo, Italy; ²Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; ³Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; ⁴Fondazione ARTET Onlus, Bergamo, Italy; ⁵ERN EuroBloodNet; ⁶School of Medicine and Surgery, University of Milan Bicocca, Italy; *On Behalf Of The Hypercan Investigators

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.536

  508

  PDF: 110
• 

  PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati^1|2, P. Gomez-Rosas^1|3, C. Ambaglio¹, V. Brusegan¹, O.C. Cretu¹, E. Galimberti¹, F. Zunino¹, L. Barcella¹, J. Harenberg^4|5, A. Falanga^1|2, M. Marchetti^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ⁴Ruprecht Karls University of Heidelberg, Heidelberg, Germany; ⁵DOASENSE GmbH, Heidelberg, Germany

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.522

  454

  PDF: 96
• 

  PO17 | PREDICTIVE VALUE OF INFLAMMATORY AND ENDOTHELIAL BIOMARKERS FOR CANCER RISK IN HEALTHY INDIVIDUALS: EVIDENCE FROM THE HYPERCAN STUDY C. Ticozzi¹, S. Bolognini^1|2, P. Gomez-Rosas^1|3, F. Schieppati^1|2, G. Sampietro⁴, L. Barcella¹, M. Marchetti^1|2, A. Falanga^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; ⁴Unit of Epidemiology and Statistics, ATS Bergamo, Italy

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.512

  442

  PDF: 99

• CO035 | THE ROLE OF INFLAMMATORY BIOMARKERS IN IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA F. Schieppati^1|2, S. Bolognini^1|2, C. Ticozzi¹, O.C. Cretu¹, P. Gomez-Rosas^1|3, M. D’Adda⁴, V. Cancelli⁴, C. Ambaglio¹, E. Galimberti¹, L. Barcella¹, A. Falanga^1|2, M. Marchetti^1|2 | ¹Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ERN-EuroBloodNet - European Reference Network in Rare Hematological Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ⁴Hematology, Hospital Spedali Civili di Brescia, Brescia, Italy

  Francesca Schieppati

  26-10-2026

  https://doi.org/10.4081/btvb.2026.737

  28

  PDF: 10